[go: up one dir, main page]

TW200407309A - 1,2-Azole derivatives - Google Patents

1,2-Azole derivatives

Info

Publication number
TW200407309A
TW200407309A TW092113937A TW92113937A TW200407309A TW 200407309 A TW200407309 A TW 200407309A TW 092113937 A TW092113937 A TW 092113937A TW 92113937 A TW92113937 A TW 92113937A TW 200407309 A TW200407309 A TW 200407309A
Authority
TW
Taiwan
Prior art keywords
ring
substituents
bond
carbon atoms
different
Prior art date
Application number
TW092113937A
Other languages
English (en)
Inventor
Tsuyoshi Maekawa
Ryoma Hara
Hiroyuki Odaka
Hiroyuki Kimura
Hideva Mizufune
Fukatsu Kohji
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of TW200407309A publication Critical patent/TW200407309A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW092113937A 2002-05-24 2003-05-23 1,2-Azole derivatives TW200407309A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002151405 2002-05-24
JP2002287161 2002-09-30
JP2003016748 2003-01-24

Publications (1)

Publication Number Publication Date
TW200407309A true TW200407309A (en) 2004-05-16

Family

ID=29587460

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092113937A TW200407309A (en) 2002-05-24 2003-05-23 1,2-Azole derivatives

Country Status (8)

Country Link
US (1) US20060148858A1 (zh)
EP (1) EP1513817A1 (zh)
AR (1) AR040043A1 (zh)
AU (1) AU2003241173A1 (zh)
CA (1) CA2487315A1 (zh)
PE (1) PE20040516A1 (zh)
TW (1) TW200407309A (zh)
WO (1) WO2003099793A1 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
AU2003296404A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heterocyclic ppar modulators
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315569A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315573A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
JP4922615B2 (ja) 2003-11-26 2012-04-25 武田薬品工業株式会社 受容体機能調節剤
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
RU2375357C2 (ru) * 2004-03-09 2009-12-10 Ф.Хоффманн-Ля Рош Аг Производные пиразолилиндолила в качестве активаторов ppar
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005099759A1 (ja) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び/又は治療のための医薬
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006042245A1 (en) * 2004-10-11 2006-04-20 Dr. Reddy's Laboratories Ltd. Novel isoxazole compounds having ppar agonist activity
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
JP5028597B2 (ja) * 2005-05-23 2012-09-19 公益財団法人相模中央化学研究所 ピラゾール−1−カルボン酸エステル誘導体、その製造方法及びピラゾール誘導体類の製造方法
JPWO2006126514A1 (ja) 2005-05-27 2008-12-25 塩野義製薬株式会社 イソキサゾール骨格を有するアリール酢酸誘導体
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
EP2043970B1 (en) * 2006-07-05 2018-04-18 Centre National De La Recherche Scientifique (C.N.R.S.) Iron-copper co-catalyzed process for carbon-carbon or carbon-heteroatom bonding
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
JPWO2008093639A1 (ja) * 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
BRPI0807014A2 (pt) * 2007-02-09 2014-04-22 Takeda Pharmaceutical Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
MX2010003876A (es) 2007-10-10 2010-12-02 Amgen Inc Moduladores de gpr40 bifenilo- sustituidos.
PT2227467E (pt) 2007-12-04 2015-03-02 Hoffmann La Roche Derivados de isoxazol-piridina
NZ588011A (en) 2008-03-05 2012-06-29 Takeda Pharmaceutical Heterocyclic compounds having glucagon antagonistic action useful for treating diabetes
EP2260017A1 (en) 2008-03-06 2010-12-15 Amgen, Inc Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8648208B2 (en) 2008-04-15 2014-02-11 Nippon Chemiphar Co. Ltd. Activating agent for peroxisome proliferator activated receptor
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
NZ592603A (en) * 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
CA2885645A1 (en) * 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2891574A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
SG11201607267SA (en) 2014-03-07 2016-09-29 Biocryst Pharm Inc Human plasma kallikrein inhibitors
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN110143910B (zh) * 2019-06-03 2022-04-05 华侨大学 一种多取代吡咯烷酮衍生物的制备方法
EP4085056A1 (en) 2020-01-03 2022-11-09 Berg LLC Polycyclic amides as ube2k modulators for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
DE3836581A1 (de) * 1988-10-27 1990-05-03 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeuremethylester und ihre verwendung
US5166216A (en) * 1988-10-27 1992-11-24 Basf Aktiengesellschaft Methyl α-arylacrylates substituted by a heterocyclic radical and their use
ATE121080T1 (de) * 1989-12-13 1995-04-15 Mitsubishi Chem Corp Pyrazolylacrylsäure-derivate, verwendbar als systemische fungiziden in pflanzen- und materialschutz.
EP0442448A3 (en) * 1990-02-13 1992-08-12 Bristol-Myers Squibb Company Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US4956376A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Tetrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5236938A (en) * 1991-04-30 1993-08-17 Rhone-Poulenc Inc. Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles
DE4116090A1 (de) * 1991-05-17 1992-11-19 Basf Ag (alpha)-phenylacrylsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen und schadpilzen
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
DE4124989A1 (de) * 1991-07-27 1993-02-04 Basf Ag (beta)-substituierte zimtsaeurederivate
DE4126994A1 (de) * 1991-08-16 1993-02-18 Basf Ag (alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
EP0581095A2 (de) * 1992-07-24 1994-02-02 BASF Aktiengesellschaft Substituierte Acrylsäureester und diese enthaltende Pflanzenschutzmittel
DE4305502A1 (de) * 1993-02-23 1994-08-25 Basf Ag Ortho-substituierte 2-Methoxyiminophenylessigsäuremethylamide
DE4338104A1 (de) * 1993-11-08 1995-05-11 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
KR970006238B1 (en) * 1994-03-15 1997-04-25 Korea Res Inst Chem Tech Propenoic ester derivatives having 4-hydroxy pyrazole group
IL113414A (en) * 1994-05-03 2000-08-13 Basf Ag Substituted methyl alpha-phenylbutenoates their preparation and use for combating harmful fungi and animal pests
EP0691332B1 (de) * 1994-07-06 1999-09-08 Basf Aktiengesellschaft Pyrazolylderivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
BR9608148A (pt) * 1995-05-09 1999-02-09 Basf Ag Composto de (het) arilóxi- -tio -e-aminocrotonato processos para sua preparação e para o controle de pestes fúngicas composição que é adequado para controlar pestes animais ou pestes fúngicas e uso de compostos
DE19519041A1 (de) * 1995-05-24 1996-11-28 Basf Ag Azolyloxybenzyl-alkoxyacrylsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2740135B1 (fr) * 1995-10-20 1997-12-19 Roussel Uclaf Nouveaux derives de pyrazoles acides, leur procede de preparation, leur application a titre de medicaments, leur nouvelle utilisation et les compositions pharmaceutiques les renfermant
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CO5060426A1 (es) * 1997-03-10 2001-07-30 Rhone Poulenc Agrochimie 1-aril-3-imidiopirazoles plaguicidas
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CN1117080C (zh) * 1997-09-05 2003-08-06 巴斯福股份公司 (杂)芳族羟胺化合物的制备方法
US6080839A (en) * 1998-06-25 2000-06-27 Wallac Oy Labeling reactants and their use
EE200100558A (et) * 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL149493A0 (en) * 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1285914B1 (en) * 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds

Also Published As

Publication number Publication date
AU2003241173A1 (en) 2003-12-12
CA2487315A1 (en) 2003-12-04
AU2003241173A8 (en) 2003-12-12
WO2003099793A8 (en) 2004-12-29
WO2003099793A1 (en) 2003-12-04
US20060148858A1 (en) 2006-07-06
EP1513817A1 (en) 2005-03-16
AR040043A1 (es) 2005-03-09
WO2003099793A9 (en) 2005-02-10
PE20040516A1 (es) 2004-10-01

Similar Documents

Publication Publication Date Title
TW200407309A (en) 1,2-Azole derivatives
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
TW200700397A (en) Novel hsp90 inhibitor
DK1533292T3 (da) Dibenzylaminforbindelse og medicinsk anvendelse deraf
TW200510440A (en) Novel compounds
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
MY142807A (en) Benzimidazole derivative and use thereof.
MY142768A (en) Gfat inhibitors
AU747521C (en) Cycloalkene derivatives, process for producing the same, and use
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
MY136824A (en) Substituted benzoxazinones and uses thereof
TW200612920A (en) Novel imidazolidine derivatives
MX2010001566A (es) Derivado de aminopirazolamida.
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MY161992A (en) Novel tetrahydroisoquinoline derivative
SG146681A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
GB0317920D0 (en) Solid-phase synthesis
TW200745033A (en) Oxindole derivative as feeding control agent